José Mauro Kutner

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background aims. Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) for use in patients who have developed resistance or clinical progression with imatinib. There are few cases described in the literature regarding the development of Philadelphia (Ph)-negative lymphoid blast crisis in patients with a complete cytogenetic response to TKI.(More)
  • 1